Literature DB >> 15820153

In vivo hierarchy of immunodominant and subdominant HLA-A*0201-restricted T-cell epitopes of HBx antigen of hepatitis B virus.

Silvina Malmassari1, Yu Chun Lone, Menghua Zhang, Catherine Transy, Marie-Louise Michel.   

Abstract

A polyepitopic CD8+ T-cell response is critical for the control of hepatitis B virus (HBV) infection. The HBV X protein (HBx) is a multifunctional protein that is important for the viral life cycle and for host-virus interactions. The aim of this study was to analyze the immunogenicity and dominance of various HLA-A*0201-restricted HBx-derived epitopes. For this purpose, we immunized HLA-A*0201-transgenic mice with HBx-derived peptides and DNA. This is a powerful model for studying the induction of HLA-A*0201-restricted immune responses in vivo, as these mice possess a cytotoxic T lymphocyte (CTL) repertoire representative of HLA-A2.1 individuals. We used cytotoxic tests and enzyme-linked immunosorbent spot (ELISPOT) assays to study the induction of specific cytotoxic and interferon (IFN)-gamma-secreting T cells. This allowed us to classify the HBx epitopes according to their T-cell activation capacity. After endogenous processing of the antigen synthesized in vivo after DNA-based immunization, we found that the HBx-specific T-cell response is targeted against one immunodominant epitope. Furthermore, following peptide immunization, we identified six additional novel subdominant T-cell epitopes. Inclusion of well-characterized epitopic sequences of HBx in a new vaccine for chronic HBV infections could help to broaden the T-cell response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15820153     DOI: 10.1016/j.micinf.2004.12.022

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  7 in total

1.  Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans.

Authors:  William G H Abbott; Peter Tsai; Euphemia Leung; Alex Trevarton; Malakai Ofanoa; John Hornell; Edward J Gane; Stephen R Munn; Allen G Rodrigo
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

2.  Mechanisms for enhanced antitumor immune responses induced by irradiated hepatocellular carcinoma cells engineered to express hepatitis B virus X protein.

Authors:  Anliang Huang; Jinhu Ma; Liyan Huang; Fan Yang; Ping Cheng
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

3.  Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters.

Authors:  Su-Ru Lin; Ta-Yu Yang; Cheng-Yuan Peng; You-Yu Lin; Chia-Yen Dai; Hurng-Yi Wang; Tung-Hung Su; Tai-Chung Tseng; I-Jung Liu; Huei-Ru Cheng; Yueh-Chi Shen; Fang-Yi Wu; Chun-Jen Liu; Ding-Shinn Chen; Pei-Jer Chen; Hung-Chih Yang; Jia-Horng Kao
Journal:  JHEP Rep       Date:  2021-02-18

Review 4.  A Systematic Review of T Cell Epitopes Defined from the Proteome of Hepatitis B Virus.

Authors:  Yandan Wu; Yan Ding; Chuanlai Shen
Journal:  Vaccines (Basel)       Date:  2022-02-08

5.  MHC Class I Presented T Cell Epitopes as Potential Antigens for Therapeutic Vaccine against HBV Chronic Infection.

Authors:  Joseph D Comber; Aykan Karabudak; Vivekananda Shetty; James S Testa; Xiaofang Huang; Ramila Philip
Journal:  Hepat Res Treat       Date:  2014-05-26

6.  Hepatitis B virus X protein binding to hepsin promotes C3 production by inducing IL-6 secretion from hepatocytes.

Authors:  Mingming Zhang; Jianxin Gu; Chunyi Zhang
Journal:  Oncotarget       Date:  2016-02-16

7.  Impact of Anti PD-1 Immunotherapy on HIV Reservoir and Anti-Viral Immune Responses in People Living with HIV and Cancer.

Authors:  Marine Baron; Cathia Soulié; Armelle Lavolé; Lambert Assoumou; Baptiste Abbar; Baptiste Fouquet; Alice Rousseau; Marianne Veyri; Assia Samri; Alain Makinson; Sylvain Choquet; Julien Mazières; Solenn Brosseau; Brigitte Autran; Dominique Costagliola; Christine Katlama; Jacques Cadranel; Anne-Geneviève Marcelin; Olivier Lambotte; Jean-Philippe Spano; Amélie Guihot
Journal:  Cells       Date:  2022-03-17       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.